Though improving renal dysfunction was not the focus of the present study, the results in the IP cohort differ from those reported by Wu et al. who saw significantly decreased proteinuria with CXCL13 blockade in MRL/lpr mice (17). Here, CXCL13 is linked to incontinentia pigmenti.